Non-alcoholic Fatty Liver Disease Parametric PET (FLiPP) Study

University of California (UC) Davis logo

University of California (UC) Davis


Active, not recruiting


Non-alcoholic Steatohepatitis (NASH)
Non-alcoholic Fatty Liver Disease (NAFLD)


Radiation: Fluorodeoxyglucose (FDG) positron emission tomography (PET)
Other: Magnetic resonance imaging (MRI)
Radiation: PET Explorer

Study type


Funder types



R01DK124803-01A1 (U.S. NIH Grant/Contract)

Details and patient eligibility


The goal of this study is to evaluate non-invasive imaging techniques for determining liver steatosis (fat), inflammation (abnormal tissue swelling), and fibrosis (abnormal tissue scarring).In addition, the study group will be using other test measures including personal demographics, laboratory blood test results, and imaging measurements to determine the severity of NAFLD (non-alcoholic fatty liver disease), NASH (non-alcoholic steatohepatitis), inflammation, and fibrosis.

Full description

The study group proposes to evaluate the role of fluorodeoxyglucose (FDG) positron emission tomography (PET) in the determination of steatohepatitis and in combination with MRI for detection, differentiation and quantitation of liver steatosis, steatohepatitis and fibrosis in correlation to liver biopsy. Patient enrolled in this will already have had their liver biopsy or will be undergoing liver biopsy as a part of their clinical care as determined by their provider and will not be getting biopsies solely to be enrolled in the study. Current treatment options for patients that liver biopsy is being performed are limited to lifestyle changes and vitamin E for patients without diabetes.


120 estimated patients




18+ years old


No Healthy Volunteers

Inclusion criteria

  • Patients >18 years age
  • Patients who had or will have a liver biopsy as standard of care for fatty liver disease and have risk factors for NASH. Liver biopsy needs to be within 6 months of planned imaging.
  • Patients undergoing bariatric surgery and will have a liver biopsy as standard of care.
  • Ability to provide informed consent.

Exclusion criteria

  • History of alcohol abuse, chronic hepatitis B or C, or other chronic liver disease other than non-alcoholic fatty liver disease.
  • Pregnant women
  • Prisoners
  • Claustrophobic to MRI
  • Allergic to FDG dye
  • Patients who are unable to lie in the scanner for one hour

Trial contacts and locations



Central trial contact

Sandeep Dhaliwal, M.D.; Valentina Medici, M.D.

Data sourced from

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems